CD14 and cancer: Peripheral blood CD8+ T cells derived from HLA-A*02:01 or HLA-A*24:02-positive healthy donors were co-cultured with autologous CD14-ML-DCs pre-loaded with a mixture of 4 kinds of previously identified cancer antigen-derived peptides (CDCA156-64, KIF20A66-75, LY6K177-186 and IMP-3508–516 for HLA-A*24:02; CDCA1351-359, KIF20A809-817, MART126-35 and IMP3515-523 for HLA-A*02:01).